The first Teladoc Health trade was made in Q1 2017.
Since then Baillie Gifford bought shares nineteen more times and sold shares on nine occasions. The investor completely sold their stake between Q2 2023 and Q1 2024.
Avg closing price
Price range
Sold -1.59M shares
Q1 2024
Avg closing price
$18.15
Price range
$14.39
-
$22.03
Sold 9.7% shares (-170k shares)
Q4 2023
Avg closing price
$18.45
Price range
$15.57
-
$22.10
Sold 0.9% shares (-16.7k shares)
Q3 2023
Avg closing price
$23.34
Price range
$18.53
-
$29.77
Sold 63.2% shares (-3.05M shares)
Q2 2023
Avg closing price
$25.17
Price range
$22.42
-
$28.17
Increased shares by 1.7% (+79.7k shares)
Q1 2023
Avg closing price
$26.76
Price range
$22.29
-
$33.20
Sold 9.5% shares (-498k shares)
Q4 2022
Avg closing price
$26.96
Price range
$22.83
-
$33.31
Sold 32.2% shares (-2.49M shares)
Q3 2022
Avg closing price
$35.08
Price range
$25.35
-
$43.66
Sold 27.9% shares (-2.99M shares)
Q2 2022
Avg closing price
$42.47
Price range
$28.63
-
$75.86
Sold 1.4% shares (-149k shares)
Q1 2022
Avg closing price
$72.04
Price range
$50.79
-
$95.08
Increased shares by 23.5% (+2.07M shares)
Q4 2021
Avg closing price
$119.52
Price range
$87.43
-
$154.29
Increased shares by 4.6% (+388k shares)
Q3 2021
Avg closing price
$145.59
Price range
$125.92
-
$164.64
Increased shares by 6.0% (+478k shares)
Q2 2021
Avg closing price
$162.03
Price range
$132.71
-
$192.38
Increased shares by 9.7% (+700k shares)
Q1 2021
Avg closing price
$231.95
Price range
$171.30
-
$294.54
Increased shares by 16.0% (+997k shares)
Q4 2020
Avg closing price
$203.34
Price range
$172.44
-
$231.80
Increased shares by 4.6% (+276k shares)
Q3 2020
Avg closing price
$211.77
Price range
$183.75
-
$249.42
Increased shares by 3.3% (+192k shares)
Q2 2020
Avg closing price
$175.25
Price range
$139.10
-
$204.94
Increased shares by 0.7% (+41.8k shares)
Q1 2020
Avg closing price
$116.34
Price range
$82.96
-
$167.44
Increased shares by 52.6% (+1.97M shares)
Q4 2019
Avg closing price
$76.10
Price range
$61.54
-
$85.88
Increased shares by 325.3% (+2.87M shares)
Q3 2019